Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22228923 | 0.91 | FOLH1 (0.42) | CTSKBCHEACHE | |
| SCHEMBL30627708 | 0.84 | FOLH1 (0.43) | CTSKCA1CA2P2RY12 | |
| SCHEMBL30892645 | 0.83 | ALB (0.43) | CTSKBCHEACHECA1CA2 | |
| SCHEMBL31317985 | 0.80 | POLB (0.40) | CA1CA2P2RY12HPGD | |
| SCHEMBL31318002 | 0.80 | ALB (0.41) | CA1CA2P2RY12 | |
| SCHEMBL31317984 | 0.80 | ALB (0.45) | CA1CA2P2RY12 | |
| SCHEMBL31317971 | 0.79 | ALB (0.43) | CA1CA2P2RY12 | |
| SCHEMBL28873551 | 0.79 | HPGD (0.50) | CA1CA2STSHPGDCNR1 | |
| SCHEMBL28299017 | 0.78 | HPGD (0.49) | CA1CA2HSD17B10STSHPGD | |
| SCHEMBL30627711 | 0.76 | FOLH1 (0.39) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA3, PSMA6, PSMA7 | CTSK 571/4885BCHE 689/4885ACHE 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.